Kiniksa Pharmaceuticals (KNSA)

• Market cap: $1.63B
• 1 day: -0.31%
• 5 days: 5.90%
• 1 month: 14.15%
• 3 months: 11.04%
• 6 months: -11.20%
• Year to date: 12.49%
• 1 year: 9.63%
• 5 years: 44.52%
• 10 years: 15.20%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

3% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 58

1% less call options, than puts

Call options by funds: $2.39M | Put options by funds: $2.41M

4.25% less ownership

Funds ownership: 98.08% [Q3] → 93.83% (-4.25%) [Q4]

10% less funds holding

Funds holding: 175 [Q3] → 158 (-17) [Q4]

22% less capital invested

Capital invested by funds: $996M [Q3] → $772M (-$224M) [Q4]

44% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 34

67% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $40 78% upside
• Avg. target: $40 78% upside
• High target: $40 78% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Geoff Meacham 63% 1-year accuracy 19 / 30 met price target

78% upside $40

Buy Initiated

13 Mar 2025